Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

PREOS NPS (Allelix/Nycomed).

Helen White1, Aftab Ahmad

  • 1Royal Liverpool University Hospital, Department of Endocrinology, Liverpool, UK. h.white@ukf.net

Current Opinion in Investigational Drugs (London, England : 2000)
|November 2, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of Albumin Nanocarriers for Enhanced Curcumin Delivery and In Vitro Anticancer Activity in Colon Cancer Cells.

Pharmaceuticals (Basel, Switzerland)·2026
Same author

Comparative Efficacy of Four Different Types of Medicaments for Pulpotomy of Primary Molars: A Clinical and Radiographic Study.

International journal of clinical pediatric dentistry·2026
Same author

Macrophage in the crosshairs: chemical inhalation and lung immune defense.

American journal of physiology. Lung cellular and molecular physiology·2026
Same author

Kaempferol-loaded solid lipid nanoparticles attenuate cartilage degradation and inflammation by modulating the expression of pro and inflammatory cytokines, MMP-13 and oxidative stress markers in adjuvant induced arthritic rats.

Inflammopharmacology·2026
Same author

Rosemary leaves extract mediated green synthesis of silver functionalized BiFeO<sub>3</sub> nanoparticles with improved visible light photocatalytic performance.

Discover nano·2026
Same author

CRISPR/Cas9-mediated editing of the <i>GhJAZ2</i> gene improves fiber length and lint percentage in <i>Gossypium hirsutum</i> L.

GM crops & food·2026
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

NPS Allelix and Nycomed are developing PREOS, an injectable recombinant human parathyroid hormone, for osteoporosis treatment. A US market authorization application was accepted for review in July 2005.

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Osteoporosis is a significant public health concern characterized by low bone mass and microarchitectural deterioration.
  • Current treatments for osteoporosis aim to reduce fracture risk, but novel therapeutic approaches are continually sought.

Purpose of the Study:

  • To summarize the development status of PREOS (recombinant human parathyroid hormone) for osteoporosis treatment.
  • To report the regulatory progress of PREOS in the United States.

Main Methods:

  • Review of publicly available information regarding PREOS development and regulatory filings.
  • Identification of key milestones in the market authorization process.

Main Results:

  • PREOS is an injectable therapeutic agent under development by NPS Allelix and Nycomed.

Related Experiment Videos

  • A market authorization application for PREOS was filed in the US in May 2005.
  • The application was accepted for regulatory review in July 2005.

    • Conclusions:

    • PREOS represents a potential new treatment option for osteoporosis.
    • The acceptance of the market authorization application signifies progress in bringing PREOS to patients.